Immuron Ltd (IMRN) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)

MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immuron Travelan® continued strong sales growth

Sales Highlights: Global December 2024 Quarter AUD$2.5 million up 70% on prior quarter, up 249% on pcpDecember...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immuron Announces New Research Collaboration targeting Antimicrobial Resistance

Highlights: New Research Collaboration with Monash University One proposal will target Antimicrobial Resistant...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immuron Announces Travelan® Clinical Trial Update

Highlights: Travelan® (IMM-124E) Phase 2 Clinical Study Report submitted to the FDATravelan® (IMM-124E) Phase...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

UPDATE: Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing

NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...

Small Cap Growth Virtual Investor Conference Agenda Announced for December 5th

NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...